Pre-formulation strategy for liposome encapsulation of new thioctic acid conjugates for enhanced chemical stability and efficient drug carrier for MPO-Mediated atherosclerotic CVD treatment

Premkumar Jayaraj ^a, Gopal Venkatesh Shavi ^b, Anandakumar Srinivasan ^c, Ramesh Raghavendra ^b, Akella Sivaramakrishna ^a, Desikan Rajagopal ^{*a,d}




Figure S1a. Proton NMR spectrum for Conjugate 1.





Figure S1b. Carbon NMR spectrum for Conjugate 1.

Figure S1c. LC-ESI-Mass spectrum for Conjugate 1.






Figure S2a. Proton NMR spectrum for Conjugate 2.

Figure S2b. Carbon NMR spectrum for Conjugate 2.




Figure S2c. LC-ESI-Mass spectrum for Conjugate 2.




Table S1. Chemical stability of Conjugates **1** and **2** (plain conjugates as well as liposome loaded) in simulated body fluid at 48 h and 72 h. Appearance of intact conjugate, hydrolyzed conjugate of alcohol and acid (+ indicates presence and – indicates absence).

Conjugate	Intact Product	Presence of alcohol	Presence of acid
Conjugate 1-Plain	+	+	+
Conjugate 1-liposome Loaded at 48 h	+	-	_
Conjugate 1-liposome Loaded at 72 h	+	_	-
Conjugate 2 -Plain	+	+	+
Conjugate 2-liposome Loaded at 48 h	+	-	-
Conjugate 2-liposome Loaded at 72 h	+	_	_